Issue of Equity
Successful placing provides funding for completion of Phase III Lupuzor™ Trial
Furthermore, as outlined in the Placing and Subscription Announcement, the Company has applied to HM Revenue and Customs to receive VCT Advance Assurance and / or EIS Advance Assurance but, as of the date of this announcement, the Advance Assurances have not yet been received. The issue of any EIS Shares and the VCT Shares within the Placing, amounting to 2,856,539 Ordinary Shares which would raise a further
Application will be made to the
Following the issue of the New Ordinary Shares referred to above, ImmuPharma will have 118,924,680 Ordinary Shares in issue. No Ordinary Shares are held in treasury. Shareholders may use the above figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under section 5 of the FCA's Disclosure and Transparency Rules.
For further information please see the Company's website, www.immupharma.org, or contact:
Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations
|
+ 44 (0) 20 7152 4080
+ 44 (0) 7721 413496 |
Panmure Gordon (Financial Adviser, Nominated Adviser & Broker) Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking
|
+44 (0) 20 7886 2500 |
All defined terms used in this announcement are defined, unless otherwise defined here, in the appendix to the Proposed Placing and Subscription and Notice of General Meeting announcement made on
This information is provided by RNS